Medindia

X

Monoclonal Antibody Based Products - Global Trends

Tuesday, February 2, 2010 General News J E 4
Advertisement


NEW YORK, Feb. 1 Reportlinker.com announces that a new market research report is available in its catalogue:

Monoclonal Antibody Based Products - Global Trends

http://www.reportlinker.com/p0164349/Monoclonal-Antibody-Based-Products---Global-Trends.html

Monoclonal antibodies represent one of the successes of the biotechnology industry along with a broad range of therapeutics and diagnostics. Monoclonal Antibody (MAb)-based products market is one of the fastest growing categories of the biopharmaceuticals industry. These products are of high significance for pharmaceutical industry, both in research as well as drug development activities. MAbs function as production repositories for developing drugs, and are used in the manufacture of highly specialized diagnostic products. Rapid technological advancements that enable antibodies to specifically target disease-causing cells are expected to boost prospects in the global therapeutic and diagnostic monoclonal antibodies market.

These and other market data and trends are presented in "Monoclonal Antibody-Based Products: Global Trends" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.

MONOCLONAL ANTIBODY BASED PRODUCTS BMR-1149

CONTENTS

1. METHODOLOGY 1

Study Reliability and Reporting Limitations 1

Disclaimers 2

Quantitative Techniques & Reporting Level 3

2. GLOBAL MARKET OVERVIEW AND OUTLOOK 4

MAb Market - Set for Significant Growth 4

Therapeutic mAb Market - Principal Driving Force 5

Development of New MAbs on a Fast Track 6

Genomics Research Leads Way to New Monoclonal Antibodies 6

Bright Outlook for Mabs 7

Current and Future Analysis 7

Product Segment Perspective 7

Competitive Scenario 7

Intensifying Consolidation Activity 8

Drug Developers Trying to Break the Shackles 11

Rituximab Vs. Epratuzumab 11

A Revolution Not too Far 11

Milestones in Development of MAbs 11

Focus on Unmet Medical Needs in the Emerging Markets 12

3. TRENDS AND ISSUES 12

Shift Towards Humanized and Fully Human Antibodies 12

Ageing Baby Boomers Spur MAbs Growth 12

Non-Existent Generic Competition Favors MAb Market 13

Partnerships and Collaborations Spark Increase in Profit Margins 13

Pharma Majors & CMOs Augment Investment in Mab Production 13

Rising Number of MAbs Under Clinical Trials 14

Select Clinical Trials for Monoclonal Antibodies 14

Major Monoclonal Antibodies in Phase III Trials Across the World 15

High Costs Impede MAbs Penetration 16

Opportunities in Technology Development 16

Advancements & Challenges in Antibody Production Processes 17

Increasing Demand for Protein A in Mab Manufacturing 17

FCA- A Major Cause for Discomfort in Mice 17

Innovations to Drive Growth in Anti-Ovarian Cancer Drugs Market 18

Rising Incidence of NHL to Drive Monoclonal Antibody Drug Market 18

4. PRODUCT FACTS 19

A.Therapeutics 19

Cancer 19

Other Therapeutic Mabs 20

B.Diagnostics 20

Types of Monoclonal Antibodies 20

5. CORPORATE DEVELOPMENTS 21

Callisto Merger Corporation Merges with Celldex Therapeutics 21

SDI to Develop mAbs for SAIC-F and NCI 21

HGS Reacquires Rights for TRAIL Receptor Antibodies 22

Amgen Enters into Licensing Agreement with Kyowa Hakko 22

Dyax and Sanofi-Aventis Sign Agreements 22

HGS Enters into Antibody Collaboration Agreement with Xencor 23

Amgen Introduces Vectibix 23

UCB Receives FDA Approval for Cimzia® 23

Genentech Acquires Tanox 23

Biotest Acquires Assets of Nabi Biologics 24

CMC Acquires ICOS Biologics Operation 24

Roche Takes Over THP 24

GTC and LFB Commence CD20 Monoclonal Antibody Development 25

Amgen Inks Collaboration and License Pact with Daiichi Sankyo 25

CMC Biopharmaceuticals Inks Agreement with Morphotek 26

CMC Biopharmaceuticals Inks Agreement with Biotest 26

Eli Lilly Collaborates with MacroGenics 26

Genentech Inks Global Licensing Agreement with Seattle Genetics 27

6. MAJOR PLAYERS 27

Amgen, Inc. (US) 27

BD Biosciences (US) 27

Biogen Idec Inc (US) 27

Biotest AG (Germany) 28

CMC ICOS Biologics, Inc. 28

Dendreon Corporation (US) 28

Elan Corporations Plc (Ireland) 28

Eli Lilly and Company (US) 28

Genentech, Inc. (US) 29

Human Genome Sciences, Inc. (US) 29

Immunomedics, Inc. (US) 29

Johnson & Johnson (US) 29

Centocor (US) 29

Ortho Biotech Products, L.P. (US) 30

Medarex, Inc. (US) 30

MedImmune, Inc. (US) 30

PDL BioPharma (US) 30

Schering-Plough Corporation (US) 31

Strategic Diagnostics Inc (US) 31

UCB Group (Belgium) 31

Wyeth Pharmaceuticals (US) 31

7. MARKET ANALYTICS 32

8. THE UNITED STATES 38

Therapeutic Monoclonal Antibodies Market - An Overview 38

New Heights for US Cancer Therapeutics 38

Competitive Landscape 39

Leading Products 39

9. CANADA 41

10. JAPAN 42

11. EUROPE 43

a. France 48

b. Germany 49

c. Italy 50

d. The United Kingdom 51

e. Rest of Europe 53

12. REST OF WORLD 54

Australia 54

Australia is All Set to Meet the Increasing Demand 54

India 54

EXHIBITS

Table 1: Major Acquisitions of Antibody-Focused Companies -

2007

Table 2: Market Shares of Leading Players in the Global

Monoclonal Antibody Therapy Market - 2005

Table 3: Market Shares of Leading Drugs in the Global

Therapeutic Monoclonal Antibodies Market - 2006

Table 4: Market Shares of Leading Antibody Based Products

Manufacturers in the World - 2004

Table 5: Market Shares of Leading Drugs in the Global

Monoclonal Antibody Based Products Market - 2004

Table 6: Market Shares of Leading Oncology Monoclonal

Antibodies Products in the World - 2008E

Table 7: Market Shares of Leading Antibody-Based

Anti-Inflammatory Products in the World - 2006

Table 8: Global Mab Market by Product Type - 2008

Table 9: Market Shares of Monoclonal Antibody Therapies in the

World - 2010E

Table 10: Global Market for Monoclonal Antibody Based Products

by Region for the Period 2007-2015 (Sales in US$ Million)

Table 11: Percentage Breakdown of Global Market for Monoclonal

Antibody Based Products by Region for the Years 2008 & 2012

Table 12: Global Therapeutics Market by Region for the Period

2007-2015 (Sales in US$ Million)

Table 13: Percentage Breakdown of Global Therapeutics Market

by Region for the Years 2008 & 2012

Table 14: Global Therapeutic Monoclonal Antibody Based

Products Market by Segments for the Period 2007- 2015 (Sales

in US$ Million)

Table 15: Percentage Breakdown of Global Therapeutic

Monoclonal Antibody Based Products Market by Segments for the

Years 2008 & 2012

Table 16: Global Cancer Market by Region for the Period

2007-2015 (Sales in US$ Million)

Table 17: Percentage Breakdown of Global Cancer Market by

Region for the Years 2008 & 2012

Table 18: Global Other Therapeutic Monoclonal Antibody Based

Products Market by Region for the Period 2007-2015 (Sales in

US$ Million)

Table 19: Percentage Breakdown of Global Other Therapeutic

Monoclonal Antibody Based Products Market by Region for the

Years 2008 & 2012

Table 20: Global Diagnostics Market by Region for the Period

2007-2015 (Sales in US$ Million)

Table 21: Percentage Breakdown of Global Diagnostics Market by

Region for the Years 2008 & 2012

Table 22: Market Shares of Leading Therapeutic Monoclonal

Antibodies Products in the US - 2007

Table 23: Market Shares of Leading Therapeutic Monoclonal

Antibodies Products Manufacturers in the US - 2007

Table 24: Monoclonal Antibody Based Products Market by Segment

in the US: 2007-2015 (Sales in US$ Million)

Table 25: Percentage Breakdown of Monoclonal Antibody Based

Products Market by Segment in the US for the Years 2008 & 2012

Table 26: Monoclonal Antibody Based Products Market by Segment

in Canada: 2007-2015 (Sales in US$ Million)

Table 27: Percentage Breakdown of Monoclonal Antibody Based

Products Market by Segment in Canada for the Years 2008 & 2012

Table 28: Monoclonal Antibody Based Products Market by Segment

in Japan: 2007-2015 (Sales in US$ Million)

Table 29: Percentage Breakdown of Monoclonal Antibody Based

Products Market by Segment in Japan for the Years 2008 &

2012

Table 30: Monoclonal Antibody Based Products Market by Region

in Europe: 2007-2015 (Sales in US$ Million)

Table 31: Percentage Breakdown of Monoclonal Antibody Based

Products Market by Region in Europe for the Years 2008 &

2012

Table 32: Monoclonal Antibody Based Products Market by Segment

in Europe: 2007-2015 (Sales in US$ Million)

Table 33: Percentage Breakdown of Monoclonal Antibody Based

Products Market by Segment in Europe for the Years 2008 & 2012

Table 34: Monoclonal Antibody Based Products Market by Segment

in France: 2007-2015 (Sales in US$ Million)

Table 35: Percentage Breakdown of Monoclonal Antibody Based

Products Market by Segment in France for the Years 2008 & 2012

Table 36: Monoclonal Antibody Based Products Market by Segment

in Germany: 2007-2015 (Sales in US$ Million)

Table 37: Percentage Breakdown of Monoclonal Antibody Based

Products Market by Segment in Germany for the Years 2008 &

2012

Table 38: Monoclonal Antibody Based Products Market by Segment

in Italy: 2007-2015 (Sales in US$ Million)

Table 39: Percentage Breakdown of Monoclonal Antibody Based

Products Market by Segment in Italy for the Years 2008 &

2012

Table 40: Monoclonal Antibody Based Products Market by Segment

in the UK: 2007-2015 (Sales in US$ Million)

Table 41: Percentage Breakdown of Monoclonal Antibody Based

Products Market by Segment in the UK for the Years 2008 &

2012

Table 42: Monoclonal Antibody Based Products Market by Segment

in Rest of Europe: 2007-2015 (Sales in US$ Million)

Table 43: Percentage Breakdown of Monoclonal Antibody Based

Products Market by Segment in Rest of Europe for the Years

2008 & 2012

Table 44: Monoclonal Antibody Based Products Market by Segment

in Rest of World: 2007-2015 (Sales in US$ Million)

Table 45: Percentage Breakdown of Monoclonal Antibody Based

Products Market by Segment in Rest of World for the Years

2008 & 2012

COMPANIES PROFILED

To order this report:

Diagnostics Industry: Monoclonal Antibody Based Products - Global Trends

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg Reportlinker Email: nbo@reportlinker.com US: (805)652-2626 Intl: +1 805-652-2626

SOURCE Reportlinker
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
American Heart Association, 100 Black Men of Ameri...
S
BioBehavioral Diagnostics Company Completes First ...